AR117614A1 - Forma de dosificación farmacéutica administrable por vía oral con liberación modificada - Google Patents

Forma de dosificación farmacéutica administrable por vía oral con liberación modificada

Info

Publication number
AR117614A1
AR117614A1 ARP190102037A ARP190102037A AR117614A1 AR 117614 A1 AR117614 A1 AR 117614A1 AR P190102037 A ARP190102037 A AR P190102037A AR P190102037 A ARP190102037 A AR P190102037A AR 117614 A1 AR117614 A1 AR 117614A1
Authority
AR
Argentina
Prior art keywords
diseases
modified release
pharmaceutical dosage
dosage form
administrable pharmaceutical
Prior art date
Application number
ARP190102037A
Other languages
English (en)
Inventor
Jacobs Tia Dr
Grossbach Danja Dr
Donald Bierer
Lovis Kai Dr
Julia Ksel
Schirmer Heiko Dr
Stroyer Anke Dr
Lobback Carmen Dr
Serno Peter Dr
Olenik Britta Dr
Rubenbauer Philipp Dr
Original Assignee
Bayer Ag
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Bayer Pharma AG filed Critical Bayer Ag
Publication of AR117614A1 publication Critical patent/AR117614A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/53—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/55—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a carbon atom of an unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente se refiere a formas de dosificación farmacéutica de liberación modificada que pueden administrarse por vía oral que contienen (3S)-3-(4-cloro-3-{[(2S,3R)-2-(4-clorofenill)-4,4,4,4-trifluoro-3-metilbutanoil]amino}fenil)-3-ciclopropilpropanoato de sodio, así como procesos para la preparación de las formas de dosificación y su uso para el tratamiento y/o prevención de enfermedades, en particular para el tratamiento y/o la prevención de enfermedades cardíacas, renales, pulmonares y oftalmológicas, enfermedades del sistema nervioso central, enfermedades fibróticas e inflamatorias y enfermedades metabólicas.
ARP190102037A 2018-07-24 2019-07-19 Forma de dosificación farmacéutica administrable por vía oral con liberación modificada AR117614A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18185127 2018-07-24

Publications (1)

Publication Number Publication Date
AR117614A1 true AR117614A1 (es) 2021-08-18

Family

ID=63041844

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190102037A AR117614A1 (es) 2018-07-24 2019-07-19 Forma de dosificación farmacéutica administrable por vía oral con liberación modificada

Country Status (2)

Country Link
US (1) US20200237648A1 (es)
AR (1) AR117614A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102011007272A1 (de) 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
CA3039735A1 (en) 2016-10-11 2018-04-19 Bayer Pharma Aktiengesellschaft Combination containing sgc activators and mineralocorticoid receptor antagonists
US10905667B2 (en) 2018-07-24 2021-02-02 Bayer Pharma Aktiengesellschaft Orally administrable modified-release pharmaceutical dosage form
CN113456607B (zh) * 2021-07-08 2023-03-21 南京康川济医药科技有限公司 一种沙库巴曲缬沙坦钠单层渗透泵控释片及其制备方法

Also Published As

Publication number Publication date
US20200237648A1 (en) 2020-07-30

Similar Documents

Publication Publication Date Title
AR117614A1 (es) Forma de dosificación farmacéutica administrable por vía oral con liberación modificada
DOP2021000015A (es) Forma de dosificación farmacéutica administrable por vía oral con liberación modificada
EA201990519A1 (ru) КРИСТАЛЛИЧЕСКАЯ ФОРМА (S)-7-(1-АКРИЛОИЛПИПЕРИДИН-4-ИЛ)-2-(4-ФЕНОКСИФЕНИЛ)-4,5,6,7-ТЕТРАГИДРОПИРАЗОЛО[1,5-a]ПИРИМИДИН-3-КАРБОКСАМИДА, ЕЕ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЯ
CL2021001810A1 (es) Combinación de dextrometorfano y bupropión para el tratamiento de depresión
WO2014205229A8 (en) Use of high dose pridopidine for treating huntington's disease
CL2018000811A1 (es) Formulaciones de aminoácidos de liberación modificada administradas por vía oral.
UY31609A1 (es) "(-) ácido 2-[1-(7-metil-2-(morfolin-4-il) 4-oxo-4h-pirido[1,2-a]pirimidin-9-il)etilamino]benzoico enantioméricamente puro, su uso en terapia médica, y una composición farmacéutica que lo comprende-026."
MX2024006689A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
WO2017062468A8 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
MX2021002322A (es) Nuevos metodos.
MX2018012538A (es) Agonistas del receptor activado por proliferador de peroxisoma (ppar), compuestos, composiciones farmaceuticas y metodos para usar los mismos.
EA202190334A1 (ru) Фармацевтическая лекарственная форма для перорального введения с модифицированным высвобождением
PH12020551911A1 (en) Use of riluzole oral disintigrating tablets for treating diseases
BR112023024550A2 (pt) Novos sais de n,n-dimetiltriptamina e formas de sal cristalino
MX2024007642A (es) Uso de tabletas de desintegracion oral de riluzol para tratar enfermedades.
AR115913A1 (es) Formas de dosificación oral biodisponibles, uso, métodos
AR099299A1 (es) Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
BR112015012497A2 (pt) combinações farmacêuticas
AR088845A1 (es) Composiciones farmaceuticas que contienen 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetrahidro-quinolina para el tratamiento de las enfermedades y las afecciones de la piel
BR112015015938A2 (pt) uso de cloridrato de fenilefrina e paracetamol, medicamento, método de tratamento de congestão das mucosas do trato respiratório superior em um humano adulto
BR112023025552A2 (pt) Composições estabilizadas de apilimod e usos das mesmas
UY37518A (es) Formas de dosificación de liberación modificada gastroretentivas para oprozomib y proceso para su fabricación
CO2018010142A2 (es) Proceso de preparación de fórmulas solidas de mesalazina
UY37413A (es) Formulaciones de liberación inmediata de oprozomib
AR109760A1 (es) Composiciones y métodos para tratar el mal de alzheimer y la enfermedad de parkinson